People | July 10, 2024
AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dyslipidemia is a critical risk factor for cardiovascular diseases
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Subscribe To Our Newsletter & Stay Updated
